Patients

Now for patients weighing ≥50 kg with partial-onset seizures one and done The established efficacy and tolerability
of lacosamide…
now in a single daily dose

Not an actual patient.

Request Representative/Samples

Steady 24-hour delivery with fewer fluctuations¹

Proven XR bead technology achieves once-daily dosing¹

Bioequivalent to lacosamide at steady-state blood levels¹

Once-Daily Dosing

Once-daily MOTPOLY XR is bioequivalent to twice-daily lacosamide¹

Learn More

24-hr Steady-State Delivery

Built-in time-release technology delivers steady blood levels¹

Learn More

Important Treatment Issues

Comorbidities, polypharmacy, and lifestyle may play a role when considering MOTPOLY XR for your adult patients

Learn More

Established Efficacy

Lacosamide demonstrated significant control of partial-onset seizures with or without secondary generalization^2,3

Learn More

Proven Safety

Well-established safety and tolerability profile with low risk of effects on cognition^4,5

Learn More

Click here to contact Aucta Pharmaceuticals Medical Information or call 1-800-655-9902.

INDICATION

MOTPOLY XR is indicated for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Antiepileptic drugs increase the risk of suicidal behavior and ideation. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors.

INDICATION

MOTPOLY XR is indicated for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Antiepileptic drugs increase the risk of suicidal behavior and ideation. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors.
MOTPOLY XR may cause dizziness and ataxia in patients. Advise patients not to operate machinery or motor vehicles until they know how MOTPOLY XR affects them.
Obtain ECG before beginning MOTPOLY XR, and after titration to steady-state maintenance dose in patients with underlying proarrhythmic conditions or those on concomitant medications that affect cardiac conduction. Closely monitor these patients.
MOTPOLY XR may cause syncope in patients.
Gradually withdraw MOTPOLY XR to minimize the potential of increased seizure frequency.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/multi-organ hypersensitivity has been reported and can be life-threatening or fatal. If signs or symptoms are present, immediately evaluate the patient. Discontinue MOTPOLY XR if there is no alternative etiology.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions in adults (≥10% and greater than placebo) are diplopia, headache, dizziness, nausea, and somnolence.

PREGNANCY: Based on animal data, MOTPOLY XR may cause fetal harm.

DRUG INTERACTIONS: Consider dose reduction in patients with renal or hepatic impairment taking strong inhibitors of CYP3A4 and CYP2C9.

Please refer to the full Prescribing Information and Medication Guide for MOTPOLY XR for additional important information.

References:
1. Data on file, Aucta Pharmaceuticals; 2022. 2. Chung S, Ben-Menachem E, Sperling MR, et al. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs. 2010;24(12):1041–1054. 3. Wechsler RT, Li G, French J, et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study. Epilepsia. 2014;55(7):1088-1098. 4. Vimpat [package insert]. Smyrna, GA: UCB, Inc.; 2021. 5. Biton V, Gil-Nagel A, Isojarvi J, et al. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav. 2015;52:119-127.